Pramlintide
Sources
registry, as of 2026-04-17Stale
https://clinicaltrials.gov/study/NCT06619015
Tailoring Obesity Treatment Trial. Overall status WITHDRAWN. Phases PHASE2,PHASE3. Lead sponsor Esbjerg Hospital - University Hospital of Southern Denmark. Enrollment 0. Conditions Obesity; Appetite Regulation; PreDiabetes. The two main aims of this clinical study is; 1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2. To investigate the effect of combining semaglutide and
ClinicalTrials.gov NCT06619015 protocol and results modules
registry, as of 2015-04-15Stale
https://clinicaltrials.gov/study/NCT00673387
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 636. Conditions Overweight; Obesity. A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects. nausea Placebo 4 diarrhea Placebo 5 vomiting Placebo 0 nausea Pramlintide 360 mcg 31 diarrhea Pramlintide 360 mcg 5 vomiting Pramlintide 360 mcg 6 nausea Metreleptin 5.0 mg 4 diarrhea Metreleptin 5.0 mg 3 vomiting Metreleptin 5.0 mg 3 nausea Pramlintide 180 mcg + Metreleptin 2.5 mg 27 diarrhea Pramlintide 180 mcg + Metreleptin 2.5 mg 5 vomiting Pram
ClinicalTrials.gov NCT00673387 protocol and results modules
registry, as of 2015-04-10Stale
https://clinicaltrials.gov/study/NCT00112021
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 400. Conditions Obesity. This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
ClinicalTrials.gov NCT00112021 protocol and results modules
registry, as of 2015-04-15Stale
https://clinicaltrials.gov/study/NCT00819234
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 274. Conditions Obesity. Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide a nausea 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 3 diarrhea 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 1 vomiting 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 0 nausea 360 mcg Pramlintide + 2.5 Metreleptin - Stable 2 diarrhea 360 mcg Pramlintide + 2.5 Metreleptin - Stable 2 vomiting 360 mcg Pramlintide + 2.5 Metreleptin - Sta
ClinicalTrials.gov NCT00819234 protocol and results modules
registry, as of 2015-03-06Stale
https://clinicaltrials.gov/study/NCT00402077
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 258. Conditions Overweight; Obesity. This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
ClinicalTrials.gov NCT00402077 protocol and results modules
registry, as of 2015-04-15Stale
https://clinicaltrials.gov/study/NCT01235741
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects. Overall status TERMINATED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 213. Conditions Obesity. Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1 of 2 treatment arms (pramlintide+metreleptin or plac Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population Week 1 Placebo -0.34 percentage of change in weight Baseline up to Month 6 Follow-Up Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population Week 1 Pramlintide + Metreleptin -0.26 percentage of change in weight Baseline up to Month 6 Foll
ClinicalTrials.gov NCT01235741 protocol and results modules
registry, as of 2015-06-11Stale
https://clinicaltrials.gov/study/NCT00189514
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 210. Conditions Obesity. This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
ClinicalTrials.gov NCT00189514 protocol and results modules
registry, as of 2015-06-11Stale
https://clinicaltrials.gov/study/NCT00444561
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 184. Conditions Overweight; Obesity. This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tole
ClinicalTrials.gov NCT00444561 protocol and results modules
registry, as of 2015-04-14Stale
https://clinicaltrials.gov/study/NCT00392925
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 177. Conditions Overweight; Obesity. This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously. nausea Placebo + Metreleptin 7 diarrhoea Placebo + Metreleptin 0 vomiting Placebo + Metreleptin 2 nausea Pramlintide + Placebo 8 diarrhoea Pramlintide + Placebo 3 vomiting Pramlintide + Placebo 1 nausea Participants Not Randomized to Group After Lead-In Period 10 diarrhoea Participants Not Randomized to Group After Lead-In Period 2 vomiting Participants Not Randomized to Group After Lead-In Period 3
ClinicalTrials.gov NCT00392925 protocol and results modules
registry, as of 2015-10-21Stale
https://clinicaltrials.gov/study/NCT00042601
Evaluation of the Effect of Pramlintide on Satiety and Food Intake. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 51. Conditions Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2. This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.
ClinicalTrials.gov NCT00042601 protocol and results modules
registry, as of 2018-11-16Stale
https://clinicaltrials.gov/study/NCT00690235
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia. Overall status COMPLETED. Phases PHASE4. Lead sponsor University of Texas Southwestern Medical Center. Enrollment 33. Conditions Schizophrenia; Schizoaffective Disorder; Diabetes; Weight Gain. Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.
ClinicalTrials.gov NCT00690235 protocol and results modules
registry, as of 2026-04-01Stale
https://clinicaltrials.gov/study/NCT07506369
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans. Overall status RECRUITING. Phases NA. Lead sponsor University Hospital, Gentofte, Copenhagen. Enrollment 18. Conditions Obesity & Overweight. The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabol
ClinicalTrials.gov NCT07506369 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06619015
semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide. The results from this study will contribute to identifying possible predictors of treatment r
NCT06619015 description or intervention text